Atogepant
Written and reviewed by Dr Ibrahim Imam, Consultant Neurologist. Last reviewed .
Atogepant. The dose is 10mg, 30mg or 60mg orally. It is administered once or twice daily. Fully referenced neurology checklist.
Dose
- The dose is 10mg, 30mg or 60mg orally
- It is administered once or twice daily
- It is approved for acute and preventative migraine treatment
Side effects
Locked: subscribe to see this section.
References
- Kish T. Emerging therapies for patients with difficult-to-treat migraine. P T 2018; 43:616-621.
- Ashina M, Tepper SJ, Reuter U, et al. Once-daily oral atogepant for the long-term preventive treatment of migraine: Findings from a multicenter, randomized, open-label, phase 3 trial. Headache 2023; 63:79-88.
- Lipton RB, Pozo-Rosich P, Blumenfeld A, et al. Effect of atogepant for preventive migraine treatment on patient-reported outcomes in the randomized, double-blind, phase 3 ADVANCE Trial. Neurology 2022 (Online ahead of print).
- Tassorelli C, Nagy K, Pozo-Rosich P, et al. Safety and efficacy of atogepant for the preventive treatment of episodic migraine in adults for whom conventional oral preventive treatments have failed (ELEVATE): a randomised, placebo-controlled, phase 3b trial. Lancet Neurol 2024; 23:382-392.
- Bond DS, Smith JH, Sinclair A, et al. Weight loss with atogepant in the long-term treatment of migraine: An interim analysis of a safety endpoint from a phase 3, multicenter, open-label, 156-week extension study. Headache 2026; 66:1730-1740.
